154 related articles for article (PubMed ID: 21080269)
1. [Principles and method of action of targeted therapies].
Singer CF
Wien Med Wochenschr; 2010 Nov; 160(19-20):501-5. PubMed ID: 21080269
[TBL] [Abstract][Full Text] [Related]
2. [New treatment approaches in breast cancer].
Spirig C; Thürlimann B; Huober J
Ther Umsch; 2008 Apr; 65(4):207-10. PubMed ID: 18622912
[TBL] [Abstract][Full Text] [Related]
3. Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment.
Hubalek M; Brunner C; Matthä K; Marth C
Wien Med Wochenschr; 2010 Nov; 160(19-20):506-12. PubMed ID: 20972709
[TBL] [Abstract][Full Text] [Related]
4. [Metastatic breast cancer--new methods of treatment].
Rack B; Heinemann V; Schindlbeck C; Walther J; Salat C; Sommer H
MMW Fortschr Med; 2008 Jan; 150(1-2):34-6. PubMed ID: 18300641
[No Abstract] [Full Text] [Related]
5. [Principles and method of action of targeted therapies.].
Singer CF
Wien Med Wochenschr; 2010 Aug; ():. PubMed ID: 20737225
[TBL] [Abstract][Full Text] [Related]
6. Novel approaches to advanced breast cancer: bevacizumab and lapatinib.
Mayer EL; Lin NU; Burstein HJ
J Natl Compr Canc Netw; 2007 Mar; 5(3):314-23. PubMed ID: 17439759
[TBL] [Abstract][Full Text] [Related]
7. Lapatinib: new directions in HER2 directed therapy for early stage breast cancer.
Jo Chien A; Rugo HS
Cancer Treat Res; 2009; 151():197-215. PubMed ID: 19593514
[No Abstract] [Full Text] [Related]
8. [Targeted therapies in breast cancer].
Jerusalem G; Collignon J; Rorive A; Lifrange E; André C; Martin M; Maweja S; Coucke P
Rev Med Liege; 2011; 66(5-6):379-84. PubMed ID: 21826980
[TBL] [Abstract][Full Text] [Related]
9. Her-2 targeted therapy: beyond breast cancer and trastuzumab.
Flaherty KT; Brose MS
Curr Oncol Rep; 2006 Mar; 8(2):90-5. PubMed ID: 16507217
[TBL] [Abstract][Full Text] [Related]
10. Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer.
Bedard PL; de Azambuja E; Cardoso F
Curr Cancer Drug Targets; 2009 Mar; 9(2):148-62. PubMed ID: 19275756
[TBL] [Abstract][Full Text] [Related]
11. Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer.
Cameron DA; Stein S
Nat Clin Pract Oncol; 2008 Sep; 5(9):512-20. PubMed ID: 18594499
[TBL] [Abstract][Full Text] [Related]
12. [Her2 positive breast cancer: practices].
Campone M; Berton-Rigaud D; Bourbouloux E; Sophie S; Zanetti A; Frenel JS
Bull Cancer; 2011 Feb; 98(2):154-63. PubMed ID: 21591301
[TBL] [Abstract][Full Text] [Related]
13. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
14. [Targeted therapies. New hopes, new challenges].
Barlési F
Rev Mal Respir; 2008 Jun; 25(6):661-2. PubMed ID: 18772823
[No Abstract] [Full Text] [Related]
15. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.
Scaltriti M; Rojo F; Ocaña A; Anido J; Guzman M; Cortes J; Di Cosimo S; Matias-Guiu X; Ramon y Cajal S; Arribas J; Baselga J
J Natl Cancer Inst; 2007 Apr; 99(8):628-38. PubMed ID: 17440164
[TBL] [Abstract][Full Text] [Related]
16. Treatment of metastatic ErbB2-positive breast cancer: options after progression on trastuzumab.
Spector N
Clin Breast Cancer; 2008 Mar; 8 Suppl 3():S94-9. PubMed ID: 18777948
[TBL] [Abstract][Full Text] [Related]
17. A preclinical evaluation of the PI3K alpha/delta dominant inhibitor BAY 80-6946 in HER2-positive breast cancer models with acquired resistance to the HER2-targeted therapies trastuzumab and lapatinib.
Elster N; Cremona M; Morgan C; Toomey S; Carr A; O'Grady A; Hennessy BT; Eustace AJ
Breast Cancer Res Treat; 2015 Jan; 149(2):373-83. PubMed ID: 25528022
[TBL] [Abstract][Full Text] [Related]
18. HER2 as a target for breast cancer therapy.
Tagliabue E; Balsari A; Campiglio M; Pupa SM
Expert Opin Biol Ther; 2010 May; 10(5):711-24. PubMed ID: 20214497
[TBL] [Abstract][Full Text] [Related]
19. [The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].
Dalmases A; Rojo F; Rovira A; Albanell J
Med Clin (Barc); 2013 Aug; 141(4):176-80. PubMed ID: 23809407
[No Abstract] [Full Text] [Related]
20. The emerging role of lapatinib in HER2-positive breast cancer.
Ulhoa-Cintra A; Greenberg L; Geyer CE
Curr Oncol Rep; 2008 Jan; 10(1):10-7. PubMed ID: 18366956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]